Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Fleshner

Showing results (51-60 of 266) with videos related to

Pageof 27
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 15, 2010
Does the reflexive measurement of free PSA have a role in a tertiary cancer centre?Christopher Allard, Paul Yip, Ivan Blasutig, et al.
The Journal of Urology|January 18, 2011
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrenceNathan Lawrentschuk, Kimberly Fernandes, David Bell, et al.
Prostate Cancer and Prostatic Diseases|January 4, 2022
Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trialRaj Tiwari, Katherine Lajkosz, Neil Fleshner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trialKris Wallace, Neil Fleshner, Michael Jewett, et al.
Journal of Clinical Pathology|April 5, 2007
Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumourCorwyn Rowsell, Neil Fleshner, Paula Marrano, et al.
The Journal of Urology|November 18, 2008
Defining increased future risk for prostate cancer: evidence from a population based screening cohortFritz H Schröder, Monique J Roobol, Gerald L Andriole, et al.
Cancer Medicine|March 12, 2021
Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancerTarik Benidir, Jaime Herrera-Caceres, Christopher Wallis, et al.
BJU International|March 30, 2005
An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseasesChristopher P Evans, Neil Fleshner, John M Fitzpatrick, et al.
The Journal of Urology|July 4, 2013
Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM studyDavid Margel, Indrani Nandy, Timothy H Wilson, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 27, 2019
Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysisKaleem S Atchia, Christopher J D Wallis, Neil Fleshner, et al.
Pageof 27

Showing results (51-60 of 266) with videos related to

Sort By:
Pageof 27
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 15, 2010
Does the reflexive measurement of free PSA have a role in a tertiary cancer centre?Christopher Allard, Paul Yip, Ivan Blasutig, et al.
The Journal of Urology|January 18, 2011
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrenceNathan Lawrentschuk, Kimberly Fernandes, David Bell, et al.
Prostate Cancer and Prostatic Diseases|January 4, 2022
Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trialRaj Tiwari, Katherine Lajkosz, Neil Fleshner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trialKris Wallace, Neil Fleshner, Michael Jewett, et al.
Journal of Clinical Pathology|April 5, 2007
Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumourCorwyn Rowsell, Neil Fleshner, Paula Marrano, et al.
The Journal of Urology|November 18, 2008
Defining increased future risk for prostate cancer: evidence from a population based screening cohortFritz H Schröder, Monique J Roobol, Gerald L Andriole, et al.
Cancer Medicine|March 12, 2021
Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancerTarik Benidir, Jaime Herrera-Caceres, Christopher Wallis, et al.
BJU International|March 30, 2005
An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseasesChristopher P Evans, Neil Fleshner, John M Fitzpatrick, et al.
The Journal of Urology|July 4, 2013
Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM studyDavid Margel, Indrani Nandy, Timothy H Wilson, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 27, 2019
Switching from a gonadotropin-releasing hormone (GnRH) agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysisKaleem S Atchia, Christopher J D Wallis, Neil Fleshner, et al.
Pageof 27